期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

尼洛替尼对伊马替尼耐药CML患者慢性期和加速期疗效分析 被引量：2

Efficacy of nilotinib for chronic myeloid leukemia in chronic phase and accelerated phase
下载PDF
导出
摘要 目的：研究尼洛替尼对伊马替尼耐药慢性粒细胞白血病慢性期和加速期的临床疗效及不良反应。方法选择CML慢性期患者12例，加速期患者11例，采用尼洛替尼治疗后分别对疗效、LDH 及a-HBDH及安全性进行评估。结果12例慢性期患者6例获得CHR ，获得缓解的中位数时间为35 d；加速期11名患者中3例获得CHR ，获得缓解的中位数时间为41 d。慢性期患者治疗后LDH 及a-HBDH较治疗前显著下降（P＜0．05），加速期患者经治疗后LDH 及a-HBDH较治疗前显著下降（P＜0．05）。慢性期及加速期患者治疗期间血液系统不良反应主要体现在Ⅲ～Ⅳ级PL T、WBC、HB下降，非血液系统并发症主要体现在发热、皮疹及胃肠道反应。结论尼洛替尼治疗伊马替尼耐药CM L患者具有较好的缓解率且不良反应多可耐受。 Objective To study the clinical efficacy of nilotinib for chronic myeloid leukemia （CML） in chron-ic phase and accelerated phase .Methods A total of 12 patients with CML in chronic phase ,and 11 patients in ac-celerated phase were enrolled .Clinical efficacy ,LDH ,a-HBDH ,and safety was assessed after nilotinib therapy . Results Altogether 6 of the 12 chronic cases obtained CHR ,the median remission time being 35 d;3 of the 11 ca-ses in accelerated phase obtained CHR ,the median remission time being 41d .LDH and a-HBDH decreased signifi-cantly in all patients （ P〈0 .05） .The adverse reactions were mainly PLT ,WBC and HB decline in grade Ⅲ-Ⅳ ,fe-ver ,rash and gastrointestinal reactions .Conclusion Imatinib-resistant CML patients showed effective response to nilotinib and could tolerate adverse reactions .
作者 康娅 刘华胜 张梅
机构地区 西安交通大学医学院第一附属医院血液内科
出处 《国外医学（医学地理分册）》 CAS 2014年第2期164-166,共3页 Foreign Medical Sciences：Section of Medgeography
基金 陕西省科学技术研究发展计划项目(No.2011K13-01-11) 西安交通大学医学院第一附属医院院基金(No.2010YK31)
关键词 尼洛替尼 慢性粒细胞白血病 慢性期 加速期 nilotinib chronic myelogenous leukemia chronic phase accelerated phase
分类号 R733 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1O'Dwyer M E, Swords R, Nagler A, et al. Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response [J]. Leuk Res, 2014, 38(3): 310-315.
  • 2Wang W, Li N N, Du Y, et al. FoxO3a and nilotinib-induced erythroid differentiation of CML-BC cells [J]. Leuk Res, 2013,37(10): 1309-1314.
  • 3Marchesi V. Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML [J]. Nat Rev Clin Oncol, 2013,10(5): 248-254.
  • 4Wagner M C, Dziadosz M, Melo J V, et al. Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells [J]. Leukemia, 2013, 27(7): 1567-1570.
  • 5White D L, Eadie L N, Saunders V A, et al. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells [J]. Leukemia, 2013,27(5): 1201-1204.
  • 6Otrock Z K, Mahfouz R A, Fahed Z, et al. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon [J]. Int J Hematol , 2012. 96(4): 521-524.
  • 7Goulden S, Sutcliffe F, Stevens A. NICE guidance on dasatinib, high-dose i-atinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib [J]. Lancet Oncol , 2012,13(2): 127-128.
  • 8Usuki K, Tojo A, Maeda Y, et al. Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study [J]. Int J Hematol, 2012, 95(4): 409-419.
  • 9Zhu G R, Ji 0, Ji J M, et al. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML [J]. Acta Haematol , 2012, 127(3): 152-155.
  • 10Weisberg E, Azab A K, Manley P W, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib [J]. Leukemia, 2012, 26(5): 985-990.

同被引文献21

  • 1Hochhaus A,O'Brien SG,Guilhot F,et al.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.Leukemia,2009;23(6):1054-1061.
  • 2Kantarjian HM,Giles F,Gattermann N,et al.Nilotinib(formerly AMN107),a highly selective BCR-ABL tyrosine kinase inhibitor,is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.Blood,2007;110(10):3540-3546.
  • 3le Coutre P,Ottmann OG,Giles F,et al.Nilotinib(formerly AMN107),a highly selective BCR-ABL tyrosine kinase inhibitor,is active in patients with imatinib-resistant orintolerant accelerated-phase chronic myelogenous leukemia.Blood,2007;111(4):1834-1839.
  • 4Hochhaus A,Kantarjian HM,Baccarani M,et al.Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.Blood,2007;109(6):2303-2309.
  • 5Rea D.Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic-phase chronic myeloid leukemia(CP-CML)receiving dasatinib.Haematologica,2012;97:80.
  • 6Saglio G,Kim DW,Issaragrisil S,et al.Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.New Engl J Med,2010;362(24):2251-2259.
  • 7Kantarjian H,Shah NP,Hochhaus A,et al.Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.New Engl J Med,2010;362(24):2260-2270.
  • 8Baccarani M,Deininger MW,Rosti G,et al.European Leukemianet recommendations for the management of chronic myeloid leukemia:2013.Blood,2013;122(6):872-884.
  • 9O'Brien S,Radich JP,Abboud CN,et al.Chronic myelogenous leukemia,Version 1.2014.J Nat Compr Canc Netw,2013;11(11):1327-1340.
  • 10Kantarjian HM,Giles FJ,Bhalla KN,et al.Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance:24-month followup results.Blood,2011;117(4):1141-1145.

引证文献2

二级引证文献11

国外医学（医学地理分册）
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部